SCHEMBL6330455

SCHEMBL6330455

CC(=O)N1CCc2ccc(S(=O)(=O)n3ccc4ccccc43)cc2C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.50
NOTUM Q6P988 1/20 0.50
HTT P42858 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
PKM P14618 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RAPGEF4 Q8WZA2 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPK1 P28482 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168219 0.93 HTR6 (0.54) HTR6NOTUMHTTALDH1A1MEN1
SCHEMBL6330427 0.76 ALDH1A1 (0.69) NOTUMHTTALDH1A1MEN1KMT2A
SCHEMBL11478363 0.76 NOTUM (0.58) NOTUMHTTLMNAHPGDPKM
SCHEMBL4384771 0.76 TP53 (0.59) NOTUMALDH1A1MEN1KMT2ALMNA
SCHEMBL6167732 0.76 HTR6 (0.65) HTR6HTTALDH1A1MEN1KMT2A
SCHEMBL17117360 0.76 PKM (0.54) HTR6NOTUMHTTALDH1A1MEN1
SCHEMBL1074701 0.75 NOTUM (0.56) NOTUMHTTALDH1A1LMNAHPGD
Hydrochloric Acid SCHEMBL6330320 0.75 HTR6 (0.64) HTR6HTTALDH1A1MEN1KMT2A
SCHEMBL6328762 0.74 HTR6 (0.62) HTR6HTTALDH1A1MEN1KMT2A
SCHEMBL4394801 0.74 ALDH1A1 (0.60) ALDH1A1MEN1KMT2ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849644-B2 Isoquinoline derivatives useful in the treatment of CNS disorders SMITHKLINE BEECHAM P.L.C. (GB) 2005-02-01 US disclosed
US-20040053956-A1 Isoquinoline derivatives useful in the treatment of cns disorders SMITHKLINE BEECHAM P.L.C. (GB) 2004-03-18 US disclosed
EP-1341783-A1 ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM PLC (GB) 2003-09-10 EP disclosed
WO-2002042293-A1 ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CNS DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053956-A1 Isoquinoline derivatives useful in the treatment of cns disorders INA, NLN, GRIN2C HTR6 234/4885NOTUM 3674/4885HTT 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.